For the malaria vaccine, what was the additional 2$ cost for? In the citation, it just says it is an assumed constant. Why is it per child and not per dose?
I’m wondering what factor of vaccine production across the spectrum would be most associated with lower cost. I’d imagine R&D timeframe would be a large component, but are there specific cost-related factors that you predict matter more or less? Does making a vaccine that does not require refrigeration lower the cost substantially in rollout?
For the malaria vaccine, what was the additional 2$ cost for? In the citation, it just says it is an assumed constant. Why is it per child and not per dose?
The additional $2 cost appears to be an amortization of various administration, implementation, and monitoring costs.
but are there specific cost-related factors that you predict matter more or less? Does making a vaccine that does not require refrigeration lower the cost substantially in rollout?
We haven’t looked into this in detail so it’s hard to say. Making a vaccine that does not require refrigeration would cut down on costs related to maintaining and creating a “cold chain” (continuous refrigerated storage and transportation), but I don’t anticipate these costs being that high and I’d expect them to be offset by significantly increased manufacturing costs per dose for making such a vaccine.
We’ll have more conclusions on cost and cost effectiveness in future posts.
For the malaria vaccine, what was the additional 2$ cost for? In the citation, it just says it is an assumed constant. Why is it per child and not per dose?
I’m wondering what factor of vaccine production across the spectrum would be most associated with lower cost. I’d imagine R&D timeframe would be a large component, but are there specific cost-related factors that you predict matter more or less? Does making a vaccine that does not require refrigeration lower the cost substantially in rollout?
The additional $2 cost appears to be an amortization of various administration, implementation, and monitoring costs.
We haven’t looked into this in detail so it’s hard to say. Making a vaccine that does not require refrigeration would cut down on costs related to maintaining and creating a “cold chain” (continuous refrigerated storage and transportation), but I don’t anticipate these costs being that high and I’d expect them to be offset by significantly increased manufacturing costs per dose for making such a vaccine.
We’ll have more conclusions on cost and cost effectiveness in future posts.